Breaking Finance News

BTG PLC (LON:BTG) has been reiterated to Neutral in a statement by JP Morgan Cazenove earlier today.

JP Morgan Cazenove has reiterated BTG PLC (LON:BTG) to Neutral in a statement released on 11/15/2017.

On Tuesday November 14, 2017, Peel Hunt released a statement for BTG PLC (LON:BTG) maintained the target price at 680.00GBX that suggested a downside of -0.02%.

Boasting a price of 675.50GBX, BTG PLC (LON:BTG) traded -0.07% lower on the day. With the last stock price close down 10.48% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. BTG PLC has recorded a 50-day average of 703.19GBX and a two hundred day average of 679.77GBX. Volume of trade was down over the average, with 347,453 shares of BTG changing hands under the typical 484,405

Performance Chart


With a total market value of 0 GBX, BTG PLC has price-earnings ratio of 87.33 with a one year low of 528.36GBX and a one year high of 764.58GBX .

Brief Synopsis About BTG PLC (LON:BTG)

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.